SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin gets USFDA’s nod for Albendazole Tablets

12 Jun 2020 Evaluate

Lupin has received approval for its Albendazole Tablets USP, 200 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Albenza Tablets, 200 mg, of Impax Laboratories Inc.

Albendazole Tablets USP, 200 mg, are an anthelmintic drug indicated for treatment of Parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm and for Cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm. Albendazole Tablets USP (RLD: Albenza) had an annual sales of approximately $34 million in the U.S. (IQVIA MAT April 2020).

Lupin is an innovationled transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2377.90 -81.85 (-3.33%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×